Biotechnology

Found 10,331 articles

• ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

  1/4/2018

  Binding of therapeutic antibodies to Aβ deposits in brain tissue, in particular blood vessels, is believed to underlie the development of ARIA in treated AD patients.

• Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in Europe

  1/4/2018

  Alimera submitted the results from two, randomized, double-masked, multi-center phase 3 clinical trials.

• Vifor Pharma's Veltassa Approved for Marketing in Switzerland for the Treatment of Hyperkalaemia

  1/4/2018

  Veltassa is a sodium-free potassium binder approved for the treatment of hyperkalaemia in adults.

• ChemoCentryx: Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency

  1/4/2018

  Under the terms of its kidney health alliance with VFMCRP, ChemoCentryx will receive a milestone payment triggered by this validation of the avacopan CMA application by the EMA.

• Protagonist Therapeutics Granted Two New U.S. Patents for Peptide Drug Candidates PTG-100 and PTG-300

  1/4/2018

  The new patent adds to previously granted U.S. patents No. 9,273,093 and 9,518,091, which also provide protection for the company's alpha-4-beta-7 integrin peptide inhibitors, including PTG-100.

• Medigene AG: Expitope 2.0 Helps to Identify Safer Antigens for Immunotherapy of Cancer

  1/4/2018

  MediGene AG announces that a scientific article has been published in the current issue of "BMC Cancer".

• AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01

  1/4/2018

  Six of the seven patients (86%) achieved treatment success (physician’s assessment), defined as complete resolution or significant improvement of baseline signs and symptoms.

• ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

  1/4/2018

  Lack of PMN310 binding to perivascular amyloid plaque in Alzheimer’s brain tissue may eliminate dose-limiting brain swelling seen with aducanumab.

• Penumbra Announces the Formation of Joint Venture, MVI Health

  1/4/2018

  MVI Health represents a unique partnership that brings together Sixense Enterprises, a team with deep experience and capability in virtual reality technology, and Penumbra, an innovator in the healthcare industry that is focused on developing and commercializing novel medical therapies.

• Jacobs Appointed as EPCM Contractor for New Gene Therapy Manufacturing Facility

  1/4/2018

  Under the terms of the contract, Jacobs will perform all required services to design, build and qualify the multi-product facility, which will manufacture gene therapy products upon completion.

• Berkeley Lights Announces Research Collaboration and License Agreement With Pfizer

  1/4/2018

  Through the collaboration, the companies will combine BLI's platform - which utilizes a light-based, nano-fluidic method to select, characterize, culture and export single cells - with Pfizer's expertise in gene editing, sequencing, and molecular biology, as well as B-cell screening, to help advance the research aims and influence the development of the Beacon platform.

• Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease

  1/4/2018

  Adaptive Biotechnologies announced today their partnership with Microsoft to map the genetics of the human immune system, or immunome, in order to detect cancers and other diseases in their earliest stage, when they can be more effectively treated.

• Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute

  1/4/2018

  Under the terms of the CRADA, the NCI will conduct research, including preclinical laboratory studies and a clinical trial, on rigosertib in pediatric cancer associated RASopathies.

• Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-Versus-Host Disease

  1/4/2018

  The study will be co-funded by Mount Sinai and Kamada.

• Nuevolution to Receive License Fee Payment of USD 750,000

  1/4/2018

  Nuevolution today announced that Janssen Biotech has exercised its option to license one of the research programs under the multi-target collaboration entered between the parties in October 2015 - a collaboration that was expanded further in April 2016 and March 2017.

• AvantGen and Tanabe Research Laboratories Expand Collaboration for Therapeutic Antibody Discovery

  1/4/2018

  Under the terms of the collaboration, AvantGen is responsible for generating novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform.

• Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018

  1/4/2018

  Revance expects cash burn for 2018 to be in the range of $117 to $137 million.

• Acticor Biotech Announces the Closing of a €1.7 Million Equity Financing Led by Primer Capital

  1/4/2018

  Acticor Biotech is strengthening its cash position in the perspective of the preparation of the first clinical phase II for its lead candidate, ACT017.

• Verastem Announces Increased Hercules Debt Facility

  1/4/2018

  Verastem announced its entry into an amendment to its Loan and Security Agreement with Hercules Capital, Inc., increasing its existing borrowing limit under the loan facility from $25 million to up to $50 million in financing.

• Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock

  1/4/2018

  The offering is expected to close on or about January 8, 2018, subject to customary closing conditions.